BinderLab Basel

Tmem127-mediated immune receptor degradation regulates T cell homeostasis through the common gamma chain https://www.biorxiv.org/content/10.1101/2025.07.01.662281v1

Tmem127-mediated immune receptor degradation regulates T cell homeostasis through the common gamma chain https://www.biorxiv.org/content/10.1101/2025.07.01.662281v1

The immunoproteasome disturbs neuronal metabolism and drives neurodegeneration in multiple sclerosis Neuronal proteasomal dysfunction is a hallmark of neuroinflammatory and neurodegenerative diseases. This study reveals that the interferon-induced immunoproteasome drastically decreases proteasomal ac...

Our latest work:
The immunoproteasome disturbs neuronal metabolism and drives neurodegeneration in multiple sclerosis: Cell www.cell.com/cell/fulltex...

Excited to co-found and help lead @imprintlabs.bsky.social —a focused effort to decode the immune system’s memory through cutting-edge computation and experimentation. Grateful to be on this journey with an exceptional team.

UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial The phase 2 FOCUS trial evaluated the hTERT vaccine UV1 plus pembrolizumab in recurrent/metastatic PD-L1+ head and neck cancer patients. UV1 was safe, did induce T cell responses, but it did not improve efficacy over pembrolizumab alone, suggesting limited benefit in this setting.

Online Now: UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial

Huge congrats to Christoph Schultheiß & Paul Schmidt-Barbo for this great work, and thanks to Ivona Aksentijevich & Daniel L. Kastner from NIH for their support! Read at JACI:
www.jacionline.org/article/S009...

We also developed a machine learning model that accurately distinguishes DADA2 patients from healthy individuals based solely on immune repertoire metrics, rather than sequence-level labels—shedding light on the unique immunogenetic signature of DADA2!

Excited to share our latest study on DADA2. We analyzed 52 patients, observing HGG, loss of T & B cell memory and persistent proinflammatory cytokines despite anti-TNF therapy. Notably, the B cell architecture was skewed toward IGHV4-34, a feature often seen in malignant B cells.

New Links Between Immune Dysfunction & Lymphoma Uncovered (Image: Adobe Stock, KI)

Binder Lab: Immune Changes & Lymphoma Risk
🔬 DADA2 mutations disrupt immune balance—low antibodies, memory B/T loss & inflammation. binderlab.bsky.social links IGHV4-34 B cells to autoimmunity & lymphoma. Their ML tool detects DADA2 via immune architecture! 📖 More: www.jacionline.org/article/S009...

IGLV3-21-R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia https://www.biorxiv.org/content/10.1101/2025.02.04.636461v1

Congratulations to Claudia Fischer for this achievement and also many thanks to Matthias Peipp from UKSH, Heinz Läubli and Obinna Chijikoe @biomedizin.unibas.ch as well as Marie Follo @uniklinik-fr.bsky.social and Nicholas Chiorazzi from Feinstein Institutes, NY.

IGLV3-21-R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia We previously used a disease-specific B cell receptor (BCR) point mutation (IGLV3-21-R110) for selective targeting of a poor-risk subset of chronic lymphocytic leukemia (CLL) with chimeric antigen rec...

Very happy to see this finally out @bioRxiv: We generated a bispecific antibody targeting the IGLV3-21-R110 CLL-specific driver mutation. Read here:
www.biorxiv.org/content/10.1...

We observed phenotypic differences in T cells based on production methods - even without antigen exposure. In addition, transposon-based production appears to promote an exhaustion-like phenotype via RIG-I sensing of transposase-encoding mRNA.

Happy to share our new preprint reporting a direct comparison of transposon-based and lentiviral CAR T cell manufacturing approaches. Read at @biorxivpreprint.bsky.social . doi.org/10.1101/2025...